Abstract
Type 2 diabetes mellitus(T2DM) is an prevalent multifactorial disease that has both genetic and environmental risk factors, resulting in impaired glucose homeostasis. Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the Tumor Necrosis Factor (TNF) receptor family and involves in the regulation of bone metabolism, ectopic calcification including vascular calcification processes, and endothelium regeneration. OPG is also referred to by its acronym. It is involved in ectopic calcification, which includes vascular calcification and endothelium renewal, and affects bone metabolism. Common genetic variations that are functionally significant can be found in the OPG gene, which codes for the protein. Type 2 diabetics have higher osteoprotegerin concentrations than non-diabetic subjects. OPG has the potential to function as a biomarker for type 2 diabetes. This study aims to investigate the association of polymorphism of OPG gene T950>C (rs2073617) gene to their serum levels among Iraqi patients. Using a suitable sample procedure, 65 volunteers (40 verified type 2 diabetic patients and 25 healthy Genetic polymorphism of Osteoprotegerin (OPG) gene T950>C (rs2073617) was carried out using RFLP-PCR. Serum levels of OPG were performed using by enzyme-linked immunosorbent assay technique (ELISA) using a Human- OPG kit. Based on the polymorphism of OPG gene T950>C, serum levels of OPG were higher among Type2DM patients with TT and CC genotypes than that with TC genotypes (TT, 2.6764±0.64032, CC 3.4532±1.80736 and TC 1.6103±0.07901, P < 0.05. The three genotypes for type 2 diabetes also showed an increase in the level of OPG compared to these levels for the same genotypes of the control group, although there were no significant differences. Furthermore, patients with TC genotype had the lowest OPG level with an insignificant difference compared to controls1.6103±0.07901 vs.1.5266±0.04768, P> 0.05. Polymorphism of the Osteoprotegerin (OPG) gene T950>C (rs2073617) can be associated with the serum levels of OPG among Type2DM patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
